{"success":true,"data":{"pressRelease":{"id":"160891","rtpr_id":"nNFCdNFhN-20261005","ticker":"AARD","exchange":"NASDAQ","all_tickers":["AARD"],"title":"If You Lost Money Investing in Aardvark Therapeutics, Inc. (AARD) Contact Robbins LLP for Information About Recovering Your Losses","author":"Newsfile Corp","published_at":"2026-10-05T16:15:14.839Z","article_body":"San Diego, California--(Newsfile Corp. - October 5, 2026) - Shareholder rights\nlaw firm Robbins LLP (https://api.newsfilecorp.com/redirect/gJMpzTjNpQ)\nreminds investors that a class action was filed on behalf of all persons and\nentities who purchased or otherwise acquired Aardvark Therapeutics, Inc\n(https://api.newsfilecorp.com/redirect/ppMxBua3oz). (NASDAQ: AARD) (a) common\nstock pursuant to the Company's February 13, 2025 initial public offering\n(\"IPO\") and/or (b) securities between February 13, 2025 and May 14, 2026 (the\n\"Class Period\"). Aardvark is a clinical-stage biopharmaceutical company that\nfocuses on developing small-molecule therapies designed to inhibit hunger and\ntreat metabolic diseases such as Prader-Willi Syndrome (\"PWS\"), a\nneurodevelopmental disorder that causes hyperphagia, or a feeling of extreme,\ninsatiable hunger.\n\nThe complaint alleges that Aardvark misled investors regarding the viability\nand efficacy of its lead drug candidate ARD-101.\n\nInvestors who suffered significant losses during the Class Period may be\neligible to participate in the lawsuit and should contact\n(https://api.newsfilecorp.com/redirect/YEMvPUWxow) Robbins LLP for information\nabout becoming lead plaintiff before the October 13, 2026 deadline.\n\nListen to our podcast (https://api.newsfilecorp.com/redirect/0p0z4uw5aA).\n\nWhy Was Aardvark Therapeutics Sued?\n\nThe complaint alleges that the Company's lead product candidate is ARD-101,\nwhich defendants have repeatedly described as a \"gut-restricted\"\nsmall-molecule agonist of certain TAS2Rs expressed in the gut lumen. To\nevaluate the effect of ARD-101 on hyperphagia-related behavior in patients\nwith Prader-Willi Syndrome, defendants commenced both a Phase 3 clinical\ntrial, referred to as the HERO trial, and an open-label extension.\n\nThe Offering Documents in support of the IPO informed investors that the\npreclinical data concerning ARD-101 \"suggest that ARD-101 shows potential to\nbe a well-tolerated, satiety-inducing drug.\"\n\nNotwithstanding, the complaint alleges that defendants failed to disclose\nthat:\n1. ARD-101 was less safe than defendants had led investors to believe;\n2. accordingly, ARD-101's clinical, regulatory, and commercial prospects were\noverstated; and\n3. as a result, defendants' public statements were materially false and\nmisleading at all relevant times.\nWhy Did Aardvark Stock Drop?\n\nThe complaint alleges that on February 27, 2026, Aardvark issued a press\nrelease \"announc[ing] it is voluntarily pausing the Phase 3 Hunger Elimination\nor Reduction Objective (HERO) trial.\" Aardvark attributed the decision to\n\"reversible cardiac observations at above target therapeutic doses found\nduring routine safety monitoring in a healthy volunteer study\" and said that\nit \"has voluntarily paused ongoing enrollment and dosing in the HERO trial\"\nwhile \"conducting a comprehensive review of the data to inform next steps.\" On\nthis news, Aardvark's stock price fell $7.02 per share, or 56.2%, to close at\n$5.47 per share on March 2, 2026.\n\nThen, on May 14, 2026, Aardvark issued a press release \"announc[ing] that the\nU.S. Food and Drug Administration (FDA) has placed a full clinical hold on its\ninvestigational new drug application (IND) for ARD-101 related to the\nCompany's previously announced voluntary pause.\" The press release specified\nthat \"[t]he clinical hold applies to all ongoing clinical studies under the\nIND, including the Phase 3 HERO trial (AVK-101-301) evaluating ARD-101 for the\ntreatment of hyperphagia in patients with Prader-Willi Syndrome (PWS) and the\nPhase 3 open-label extension (OLE) trial (AVK-101-302).\" On this news,\nAardvark's stock price fell $2.16 per share, or 32.1%, to close at $4.57 per\nshare on May 15, 2026.\n\nWho May Be Eligible to Participate in the AARD Class Action?\n\nThe lawsuit seeks to represent investors who purchased or otherwise acquired\n(i) Aardvark common stock pursuant to the Company's February 13, 2025 IPO;\nand/or (ii) Aardvark securities between February 13, 2025 and May 14, 2026.\nInvestors who suffered losses during that period may have legal rights under\nthe federal securities laws.\n\nWhat Is a Lead Plaintiff?\n\nThe lead plaintiff is a court-appointed investor who represents the interests\nof all class members throughout the litigation. Investors who wish to seek\nappointment as lead plaintiff must do so by October 13, 2026.\n\nServing as lead plaintiff is not required to share in any potential recovery.\nInvestors who do not seek appointment may remain absent class members if the\ncase proceeds and later resolves successfully.\n\nDoes It Cost Anything to Participate?\n\nNo. Robbins LLP represents investors on a contingency fee basis.\n\nContact Robbins LLP\n\nInvestors seeking additional information about the Aardvark Therapeutics\nsecurities class action may contact Robbins LLP by submitting\n(https://api.newsfilecorp.com/redirect/RYqXmTWwnv) an inquiry, emailing\n(mailto:adumas@robbinsllp.com) attorney Aaron Dumas, Jr., or calling (800)\n350-6003.\n\nWhy Robbins LLP?\n\nRobbins LLP (https://api.newsfilecorp.com/redirect/WAM4oHWneZ) is a\nshareholder rights law firm focused on representing investors in securities\nfraud and shareholder litigation. The firm has helped recover more than $2\nbillion for investors, obtained significant corporate governance reforms, and\nhas represented shareholders in cases involving alleged violations of the\nfederal securities laws.\n\n\"Companies have an obligation to provide investors with complete and accurate\ninformation so that markets can function fairly and efficiently,\" said Brian\nJ. Robbins, Founding Partner of Robbins LLP.\n\nTo be notified if a class action against Aardvark Therapeutics, Inc. settles\nor to receive free alerts when corporate executives engage in wrongdoing, sign\nup for Stock Watch (https://api.newsfilecorp.com/redirect/qpM75uaMOb) today.\n\nAttorney Advertising. Past results do not guarantee a similar outcome.\n\nContact:\nAaron Dumas, Jr.\nRobbins LLP\n5060 Shoreham Pl., Ste. 300\nSan Diego, CA 92122\nadumas@robbinsllp.com\n(800) 350-6003\nwww.robbinsllp.com\n\nFacebook (https://api.newsfilecorp.com/redirect/KLw7zTw3AG)\nLinkedIn (https://api.newsfilecorp.com/redirect/EZBWqf2vnr)\n\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/317268","article_body_html":"","raw_payload":{"data":{"id":"nNFCdNFhN-20261005","title":"If You Lost Money Investing in Aardvark Therapeutics, Inc. (AARD) Contact Robbins LLP for Information About Recovering Your Losses","author":"Newsfile Corp","ticker":"AARD","created":"2026-10-05T16:15:14.839Z","tickers":["AARD"],"exchange":"NASDAQ","article_body":"San Diego, California--(Newsfile Corp. - October 5, 2026) - Shareholder rights\nlaw firm Robbins LLP (https://api.newsfilecorp.com/redirect/gJMpzTjNpQ)\nreminds investors that a class action was filed on behalf of all persons and\nentities who purchased or otherwise acquired Aardvark Therapeutics, Inc\n(https://api.newsfilecorp.com/redirect/ppMxBua3oz). (NASDAQ: AARD) (a) common\nstock pursuant to the Company's February 13, 2025 initial public offering\n(\"IPO\") and/or (b) securities between February 13, 2025 and May 14, 2026 (the\n\"Class Period\"). Aardvark is a clinical-stage biopharmaceutical company that\nfocuses on developing small-molecule therapies designed to inhibit hunger and\ntreat metabolic diseases such as Prader-Willi Syndrome (\"PWS\"), a\nneurodevelopmental disorder that causes hyperphagia, or a feeling of extreme,\ninsatiable hunger.\n\nThe complaint alleges that Aardvark misled investors regarding the viability\nand efficacy of its lead drug candidate ARD-101.\n\nInvestors who suffered significant losses during the Class Period may be\neligible to participate in the lawsuit and should contact\n(https://api.newsfilecorp.com/redirect/YEMvPUWxow) Robbins LLP for information\nabout becoming lead plaintiff before the October 13, 2026 deadline.\n\nListen to our podcast (https://api.newsfilecorp.com/redirect/0p0z4uw5aA).\n\nWhy Was Aardvark Therapeutics Sued?\n\nThe complaint alleges that the Company's lead product candidate is ARD-101,\nwhich defendants have repeatedly described as a \"gut-restricted\"\nsmall-molecule agonist of certain TAS2Rs expressed in the gut lumen. To\nevaluate the effect of ARD-101 on hyperphagia-related behavior in patients\nwith Prader-Willi Syndrome, defendants commenced both a Phase 3 clinical\ntrial, referred to as the HERO trial, and an open-label extension.\n\nThe Offering Documents in support of the IPO informed investors that the\npreclinical data concerning ARD-101 \"suggest that ARD-101 shows potential to\nbe a well-tolerated, satiety-inducing drug.\"\n\nNotwithstanding, the complaint alleges that defendants failed to disclose\nthat:\n1. ARD-101 was less safe than defendants had led investors to believe;\n2. accordingly, ARD-101's clinical, regulatory, and commercial prospects were\noverstated; and\n3. as a result, defendants' public statements were materially false and\nmisleading at all relevant times.\nWhy Did Aardvark Stock Drop?\n\nThe complaint alleges that on February 27, 2026, Aardvark issued a press\nrelease \"announc[ing] it is voluntarily pausing the Phase 3 Hunger Elimination\nor Reduction Objective (HERO) trial.\" Aardvark attributed the decision to\n\"reversible cardiac observations at above target therapeutic doses found\nduring routine safety monitoring in a healthy volunteer study\" and said that\nit \"has voluntarily paused ongoing enrollment and dosing in the HERO trial\"\nwhile \"conducting a comprehensive review of the data to inform next steps.\" On\nthis news, Aardvark's stock price fell $7.02 per share, or 56.2%, to close at\n$5.47 per share on March 2, 2026.\n\nThen, on May 14, 2026, Aardvark issued a press release \"announc[ing] that the\nU.S. Food and Drug Administration (FDA) has placed a full clinical hold on its\ninvestigational new drug application (IND) for ARD-101 related to the\nCompany's previously announced voluntary pause.\" The press release specified\nthat \"[t]he clinical hold applies to all ongoing clinical studies under the\nIND, including the Phase 3 HERO trial (AVK-101-301) evaluating ARD-101 for the\ntreatment of hyperphagia in patients with Prader-Willi Syndrome (PWS) and the\nPhase 3 open-label extension (OLE) trial (AVK-101-302).\" On this news,\nAardvark's stock price fell $2.16 per share, or 32.1%, to close at $4.57 per\nshare on May 15, 2026.\n\nWho May Be Eligible to Participate in the AARD Class Action?\n\nThe lawsuit seeks to represent investors who purchased or otherwise acquired\n(i) Aardvark common stock pursuant to the Company's February 13, 2025 IPO;\nand/or (ii) Aardvark securities between February 13, 2025 and May 14, 2026.\nInvestors who suffered losses during that period may have legal rights under\nthe federal securities laws.\n\nWhat Is a Lead Plaintiff?\n\nThe lead plaintiff is a court-appointed investor who represents the interests\nof all class members throughout the litigation. Investors who wish to seek\nappointment as lead plaintiff must do so by October 13, 2026.\n\nServing as lead plaintiff is not required to share in any potential recovery.\nInvestors who do not seek appointment may remain absent class members if the\ncase proceeds and later resolves successfully.\n\nDoes It Cost Anything to Participate?\n\nNo. Robbins LLP represents investors on a contingency fee basis.\n\nContact Robbins LLP\n\nInvestors seeking additional information about the Aardvark Therapeutics\nsecurities class action may contact Robbins LLP by submitting\n(https://api.newsfilecorp.com/redirect/RYqXmTWwnv) an inquiry, emailing\n(mailto:adumas@robbinsllp.com) attorney Aaron Dumas, Jr., or calling (800)\n350-6003.\n\nWhy Robbins LLP?\n\nRobbins LLP (https://api.newsfilecorp.com/redirect/WAM4oHWneZ) is a\nshareholder rights law firm focused on representing investors in securities\nfraud and shareholder litigation. The firm has helped recover more than $2\nbillion for investors, obtained significant corporate governance reforms, and\nhas represented shareholders in cases involving alleged violations of the\nfederal securities laws.\n\n\"Companies have an obligation to provide investors with complete and accurate\ninformation so that markets can function fairly and efficiently,\" said Brian\nJ. Robbins, Founding Partner of Robbins LLP.\n\nTo be notified if a class action against Aardvark Therapeutics, Inc. settles\nor to receive free alerts when corporate executives engage in wrongdoing, sign\nup for Stock Watch (https://api.newsfilecorp.com/redirect/qpM75uaMOb) today.\n\nAttorney Advertising. Past results do not guarantee a similar outcome.\n\nContact:\nAaron Dumas, Jr.\nRobbins LLP\n5060 Shoreham Pl., Ste. 300\nSan Diego, CA 92122\nadumas@robbinsllp.com\n(800) 350-6003\nwww.robbinsllp.com\n\nFacebook (https://api.newsfilecorp.com/redirect/KLw7zTw3AG)\nLinkedIn (https://api.newsfilecorp.com/redirect/EZBWqf2vnr)\n\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/317268"},"type":"article","timestamp":"2026-10-05T16:15:14.894013417Z","server_sent_at_ms":1791216914894},"received_at":"2026-10-05T16:15:14.945Z","source_url":"https://www.newsfilecorp.com/release/317268"},"analysis":{"id":"149444","press_release_id":"160891","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":["Securities class action alleging misleading statements about ARD-101 safety and commercial prospects","Full FDA clinical hold on ARD-101 IND including Phase 3 HERO trial (as alleged in complaint)","Lead-plaintiff deadline October 13, 2026 signals active litigation overhang"],"eventType":"legal_litigation","narrative":"Shareholder rights firm Robbins LLP issued a solicitation reminding AARD investors of the October 13, 2026 lead-plaintiff deadline in a securities class action covering the February 2025 IPO and the February 13, 2025 to May 14, 2026 class period.\n\nThe complaint alleges Aardvark misled investors on the safety and prospects of lead drug candidate ARD-101, citing a voluntary pause of the Phase 3 HERO trial in February 2026 that sent the stock down 56.2% to $5.47, followed by a full FDA clinical hold in May 2026 that dropped shares another 32.1% to $4.57.\n\nThis is law-firm marketing around an existing suit, not a new issuer disclosure; treat as low-signal noise beyond confirming the litigation exists.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation on an already-filed class action -- suppress or archive."},"keyFigures":{"customDimensions":{"class_period":"February 13, 2025 to May 14, 2026","stock_drop_feb_2026":"-56.2% to $5.47 on March 2, 2026","stock_drop_may_2026":"-32.1% to $4.57 on May 15, 2026","lead_plaintiff_deadline":"October 13, 2026"}},"quotedText":"\"reversible cardiac observations at above target therapeutic doses found during routine safety monitoring in a healthy volunteer study\"","namedEntities":{"people":[{"name":"Aaron Dumas, Jr.","role":"attorney, Robbins LLP"},{"name":"Brian J. Robbins","role":"Founding Partner, Robbins LLP"}],"products":["ARD-101","HERO trial"],"companies":[{"name":"Robbins LLP","relationship":"plaintiff law firm"},{"name":"Aardvark Therapeutics, Inc.","ticker":"AARD","relationship":"class action defendant/issuer"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Robbins LLP solicitation reminding investors of the lead-plaintiff deadline in an already-filed class action against Aardvark. No new issuer disclosure, no certified class, and no settlement, though the underlying claims (trial pause, full FDA clinical hold, two large stock drops) are serious for the issuer."},"tickerRelevance":{"others":[],"primary":"AARD"},"globalImportance":15,"audienceRelevance":12,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false,"underlyingSeverityNote":"FDA clinical hold and 56% drop alleged, but release itself is marketing"}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":2,"narrative":"Shareholder rights firm Robbins LLP issued a solicitation reminding AARD investors of the October 13, 2026 lead-plaintiff deadline in a securities class action covering the February 2025 IPO and the February 13, 2025 to May 14, 2026 class period.\n\nThe complaint alleges Aardvark misled investors on the safety and prospects of lead drug candidate ARD-101, citing a voluntary pause of the Phase 3 HERO trial in February 2026 that sent the stock down 56.2% to $5.47, followed by a full FDA clinical hold in May 2026 that dropped shares another 32.1% to $4.57.\n\nThis is law-firm marketing around an existing suit, not a new issuer disclosure; treat as low-signal noise beyond confirming the litigation exists.","key_figures":{"customDimensions":{"class_period":"February 13, 2025 to May 14, 2026","stock_drop_feb_2026":"-56.2% to $5.47 on March 2, 2026","stock_drop_may_2026":"-32.1% to $4.57 on May 15, 2026","lead_plaintiff_deadline":"October 13, 2026"}},"named_entities":{"people":[{"name":"Aaron Dumas, Jr.","role":"attorney, Robbins LLP"},{"name":"Brian J. Robbins","role":"Founding Partner, Robbins LLP"}],"products":["ARD-101","HERO trial"],"companies":[{"name":"Robbins LLP","relationship":"plaintiff law firm"},{"name":"Aardvark Therapeutics, Inc.","ticker":"AARD","relationship":"class action defendant/issuer"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-05T16:15:21.469Z","global_importance":15,"audience_relevance":12,"importance_components":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false,"underlyingSeverityNote":"FDA clinical hold and 56% drop alleged, but release itself is marketing"}},"durationMs":6510,"modelName":"glm-5.3-flashx"}}